Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity.
about
Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT.Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations.Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.Elevated Voriconazole Level Associated With Hallucinations and Suicidal Ideation: A Case Report.Dosing and therapeutic drug monitoring of voriconazole in bottlenose dolphins (Tursiops truncatus).Autoinduction of voriconazole metabolism in a child with invasive pulmonary aspergillosis.Pharmacogenetics and precision medicine: Is inflammation a covert threat to effective genotype-based therapy?Voriconazole treatment in adults and children with hematological diseases: can it be used without measurement of plasma concentration?Improving survival of acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis.Population Pharmacokinetics of Voriconazole and CYP2C19 Polymorphisms for Optimizing Dosing Regimens in Renal Transplant Recipients.Issues in the management of invasive pulmonary aspergillosis in non-neutropenic patients in the intensive care unit: A role for isavuconazole.Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole
P2860
Q30491969-30487973-5704-4173-9790-F17F8B76C483Q33696043-27EE9C6A-2BA5-45DE-8128-B6A4346F574CQ34532546-A92FE89B-DFC3-49F8-9D09-E39F99ED55B2Q35954530-41723E08-6FD7-4CD2-A1DF-426B280B6FFFQ36608562-3755A37C-D09F-42A5-BD77-4C714758B12FQ38690098-E029368E-65A0-404E-AC46-2CD8B9F3B981Q38823930-B918B7D6-A6D3-4BD2-BE92-A52090096101Q38880522-0B8B1D0C-FAB3-47A7-B238-93344A6F91BAQ39127825-96A428A7-0073-46B4-A03E-721944A0080DQ40222933-8238FBD8-9D47-43C2-A38F-70D750509CECQ40487869-D21AFE07-5527-4455-A774-A03CA59D1BF5Q41057395-B18A996E-08EF-4144-9DB1-9E963F13C960Q42345777-329EBF42-9F04-4295-BA03-A73BD0CF7801Q49385523-E9AB4511-A1ED-4BFC-9AE9-8DE1335AE853Q49430203-0F37D64C-1203-4252-85D6-DA39380A620FQ52614215-D3500B2B-3768-4C1C-A1B9-0BC6BEC5A468Q55126951-FDDD3ADF-A3DA-4E76-BF91-405CA367FFCBQ57162735-B4021E7B-3825-4D92-8D39-9E919EB8BD39
P2860
Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Voriconazole pharmacokinetics ...... posure, efficacy and toxicity.
@en
type
label
Voriconazole pharmacokinetics ...... posure, efficacy and toxicity.
@en
prefLabel
Voriconazole pharmacokinetics ...... posure, efficacy and toxicity.
@en
P1476
Voriconazole pharmacokinetics ...... posure, efficacy and toxicity.
@en
P2093
Michael J Dolton
P304
P356
10.1016/J.IJANTIMICAG.2014.05.019
P577
2014-07-07T00:00:00Z